Clinical trials: Treatment as Usual Care Group
Modified DECIDE Intervention, Treatment as Usual Care Group
The DECIDE Parent-Provider Intervention
The DECIDE Parent-Provider Intervention is designed to support parents caring for adolescents who are receiving treatment for Disruptive, Impulse-Control, and Conduct disorders.
- Trial name
- NCT04445155
- Testing
- Modified DECIDE Parent and Provider Intervention
- Where
- 5 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Indiana University
Quality of Life
Effectiveness of Cognitive Behavioral Intervention in Patients With Symptoms Somatization in Primary Care
The purpose of this study is to evaluate the efectiveness of a behavioral cognitive grupal intervention (BCI) in patients with somatization symptoms which has an effect on the perceived quality of life front conventional…
- Trial name
- NCT01484223
- Testing
- Cognitive Behavioral Therapy
- Where
- Spain
- Volunteers
- 242 people
- Sponsor
- Gerencia de Atención Primaria, Madrid
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00776984
- Testing
- tiotropium 5mcg/day
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 453 people
- Sponsor
- Boehringer Ingelheim
Autism Spectrum Disorder (ASD), Anxiety
Adapted Group Therapy Compared With Usual Care for Anxiety and Depression in Adults With an Autism Diagnosis
The goal of this clinical trial is to learn whether an adapted group therapy works to treat anxiety and depression in adults with an autism diagnosis. The therapy is a form of cognitive behavioral therapy (CBT).
- Conditions
- Autism Spectrum Disorder (ASD), Anxiety, Depression
- Trial name
- CoMind (NCT07880028)
- Testing
- Autism-adapted group cognitive behavioral therapy
- Volunteers
- 154 people
- Sponsor
- Lovisenberg Diakonale Hospital
Hypertension, SMS-text
Effectiveness of SMS-text Message Support for Patients With Hypertension to Improve Blood Pressure
General synopsis for SMS-text Adherence Support (*StAR) Study and associated preparatory and pilot work Background: High blood pressure is an important risk factor for heart disease, stroke and chronic kidney disease.
- Conditions
- Hypertension, SMS-text, mHealth
- Trial name
- *StAR (NCT02019823)
- Testing
- Informational SMS-text, Interactive SMS-text, Enhanced usual care
- Volunteers
- 1,372 people
- Sponsor
- University of Oxford
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy…
- Trial name
- NCT01277523
- Testing
- tiotropium high dose, tiotropium low dose
- Where
- 69 sites in United States, Argentina and 12 more
- Volunteers
- 392 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on…
- Trial name
- NCT01634152
- Testing
- Tiotropium low dose mcg, Tiotropium high dose
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 401 people
- Sponsor
- Boehringer Ingelheim
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00772538
- Testing
- tiotropium 5mcg/day
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Boehringer Ingelheim